By vgreene, 14 June, 2019 MammaPrint assay: recommended in pts w/ 1-3 positive nodes [ASCO EV-high; REC-moderate] who ALSO have high clinical risk as defined by MINDACT categorization to inform decisions on withholding adjuvant systemic chemotx2
By vgreene, 14 June, 2019 uPA and PAI-1: to guide decisions about adjuvant systemic tx2 [ASCO EV-insufficient; REC-weak]
By vgreene, 14 June, 2019 Breast Cancer Index (BCI): to guide decisions about adjuvant systemic tx2 [ASCO EV-intermediate; REC-moderate]
By vgreene, 14 June, 2019 Breast Cancer Index (BCI): to guide decisions about adjuvant systemic tx2 [ASCO EV-intermediate; REC-moderate]
By vgreene, 14 June, 2019 PAM50: recommended in conjunction w/ other clinicopathologic variables to guide decisions about adjuvant systemic tx2 [ASCO EV-high; REC-strong]
By vgreene, 14 June, 2019 MammaPrint assay: for pts who ALSO have high clinical risk as defined by MINDACT categorization to inform decisions on withholding adjuvant systemic chemotx2 [ASCO EV-high; REC-strong]
By vgreene, 14 June, 2019 EndoPredict (12-gene risk score): to guide decisions for adjuvant systemic chemotherapy2 [ASCO EV-intermediate; REC-moderate]
By vgreene, 14 June, 2019 HER2 status testing on metastatic site by validated IHC assay or by validated dual-probe ISH assay1